Dr. Brar on the Rise of New Treatment Approaches in HCC
In Partnership With:
Gagandeep Brar, MD, discusses the rise of new treatment approaches in hepatocellular carcinoma.
Gagandeep Brar, MD, assistant professor of medicine, Division of Hematologic and Medical Oncology, Weill Cornell Medicine, discusses the rise of new treatment approaches in hepatocellular carcinoma (HCC).
Prior to 2017, HCC was a challenging disease to treat, and patients had fairly dismal prognoses, Brar says.
However, over the past 3 years, a host of new data and research efforts have emerged, Brar adds.
Notably, in light of new treatment options, patients with HCC are now experiencing prolonged survival and improved quality of life, explains Brar.
Ultimately, these developments have been encouraging in HCC and additional efforts are underway to further advance the paradigm, Brar concludes.
FDA Places Clinical Hold on Phase 1 Trial of XMT-2056 in HER2-expressing Solid Tumors
